UTHR Related StreetInsider.com Reports
-
Standpoint Research Downgrades United Therapeutics Corp. (UTHR) to Hold
-
Ladenburg Thalmann Downgrades United Therapeutics Corp. (UTHR) to Neutral
-
United Therapeutics (UTHR) Posts Q1 EPS of $1.24
-
Trading Radar for 04/25: Exxon, (XOM), Dow (DOW), 3M (MMM), Hershey (HSY), UPS (UPS), Expedia (EXPE) Report
-
United Therapeutics (UTHR) Falls after FDA Again Fails to Approve Oral Treprostinil NDA
-
Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived
-
United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
-
Trading Radar for 02/26: TiVo (TIVO), Macy's (M), Priceline.com (PCLN), RadioShack (RSH), Saks (SKS) Report
-
Trading Radar for 02/14: General Motors (GM), CBS (CBS), DirecTV (DTV), Pepsi (PEP), Orbitz (OWW) Report
-
Trading Radar for 02/12: McGraw-Hill (MHP), Clearwire (CLWR), Michael Kors (KORS), Coca-Cola (KO), Avon Products (AVP) Report
-
Standpoint Research Upgrades United Therapeutics Corp. (UTHR) to Buy
-
United Therapeutics (UTHR) Adds $420M to Buyback Plan
-
Guggenheim Starts United Therapeutics Corp. (UTHR) at Neutral
-
Notable Analyst Rating Changes 12/13: (RFMD) (AVGO) (GLF) Upgraded; (ALLT) (NBR) (LXK) Downgraded
-
Goldman Sachs Downgrades United Therapeutics Corp. (UTHR) to Sell
-
United Therapeutics (UTHR) Tops Q3 EPS by 26c; Reaffirms Outlook
-
Notable Analyst Rating Changes 10/24: (FB) (BAC) (QCOR) Upgraded; (ATML) (UTHR) (NSC) Downgraded
-
Pre-Open Movers 10/24: (SEH) (FB) (LL) Higher; (TPX) (NFLX) (DSCO) Lower (more...)
-
JPMorgan Downgrades United Therapeutics Corp. (UTHR) to Underweight
-
BMO Capital Downgrades United Therapeutics Corp. (UTHR) to Market Perform
-
After-Hours Movers 10/23: (FB) (RFMD) (PNRA) Higher; (TPX) (NFLX) (UTHR) Lower (more...)
-
United Therapeutics (UTHR) Receives CRL from FDA for Oral Treprostinil
-
Standpoint Research Downgrades United Therapeutics Corp. (UTHR) to Hold
-
Canaccord Genuity Maintains a 'Hold' on United Therapeutics (UTHR); Increasing FY12 Adcirca and Tyvaso Revenues
-
United Therapeutics (UTHR) Approves $100M Buyback
-
United Therapeutics (UTHR) Tops Q2 EPS by 22c
-
Trading Radar for 07/26: Facebook (FB), Sprint (S), Amazon (AMZN), Starbucks (SBUX), 3M (MMM), Dow (DOW), Potash (POT) Report
-
United Therapeutics (UTHR) Approves New $100M Buyback Plan
-
UPDATE - Canaccord Genuity Downgraded United Therapeutics (UTHR) to Hold; Sidelined on Uncertainty
-
Canaccord Genuity Downgrades United Therapeutics Corp. (UTHR) to Hold
-
United Therapeutics (UTHR) Tops Q1 EPS Views; Reaffirms Outlook
-
Trading Radar for 04/26: PepsiCo (PEP), Amazon.com (AMZN), Conagra (CAG), Metlife (MET), Dow Chemical (DOW), Expedia (EXPE) Report
-
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
-
Pre-Open Movers 4/12: (WAB) (MCK) (TSCO) Higher; (AVID) (APOG) (NOK) Lower (more...)
-
Leerink Swann Downgrades United Therapeutics Corp. (UTHR) to Market Perform; Generic Risk
-
Canaccord Genuity Starts United Therapeutics Corp. (UTHR) at Buy
-
Standpoint Research Starts United Therapeutics Corp. (UTHR) at Buy
-
United Therapeutics (UTHR) Reports FDA Accepts NDA for Oral Treprostinil
-
Auriga Maintains a 'Hold' on United Therapeutics (UTHR); Q4 Review
-
United Therapeutics Corp (UTHR) Reports Q4 EPS of $0.79, Reaffirms FY12, FY13 Guidance
-
Trading Radar for 02/14: Zynga (ZNGA), Avon (AVP), Goodyear (GT), Michael Kors (KORS), Metlife (MET) Report
-
United Therapeutics (UTHR) Lower As Analyst Highlights Sandoz Generic Remodulin Filing
-
United Therapeutics (UTHR) Receives Paragraph IV from Sandoz for Generic Remodulin
-
Short Interest Ticks Up in Large-Cap Biotech, Specifically Amgen (AMGN)
-
United Therapeutics (UTHR) Gets Approval from AFSSAPS for Remodulin
-
United Therapeutics (UTHR) CEO Buys 13K Shares
-
United Therapeutics Corp (UTHR) Easily Beats Q3 Views; Revs Top $200M
-
Trading Radar for 10/27: Exxon (XOM), Dow Chemical (DOW), Baidu.com (BIDU), Procter & Gamble (PG), AMD (AMD) Report
-
United Therapeutics (UTHR) Announces Accelerated Stock Buyback Plan, Authorizes $250M Notes Offering
-
United Therapeutics (UTHR) Subsidiary Awarded Contract Worth Up To $45 Million From NIAID
Back to UTHR Stock Lookup
